View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: March 21, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Dylan Shindler
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
 PRESS RELEASE

374Water to Host Fourth Quarter and Full Year 2024 Results Conference ...

374Water to Host Fourth Quarter and Full Year 2024 Results Conference Call on Thursday, March 27, 2025 at 4:30 p.m. Eastern Time DURHAM, N.C., March 20, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2024, after market close on Thursday, March 27, 2025. Following this, the Company will hold a conference call at 4:30 p.m. Eastern time to discuss i...

 PRESS RELEASE

NewtekOne, Inc. Closes Private Offering of Senior Unsecured Notes

NewtekOne, Inc. Closes Private Offering of Senior Unsecured Notes NewtekOne’s Credit Rating Upgraded by Egan-Jones BOCA RATON, Fla., March 20, 2025 (GLOBE NEWSWIRE) -- (the “Company”) (NASDAQ: NEWT) has completed an exempt offering of $30.0 million aggregate principal amount of its 8.375% notes due 2030 (the “Notes” and the "Offering"). The Offering was consummated pursuant to the terms of a purchase agreement (the “Purchase Agreement”) dated March 19, 2025 between the Company and eleven institutional accredited investors (the “Purchasers”). The Purchase Agreement provided for the Note...

David Nierengarten ... (+4)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
  • Yun Zhong
 PRESS RELEASE

374Water Announces its AirSCWO Technology is Successful in Eliminating...

374Water Announces its AirSCWO Technology is Successful in Eliminating LNAPL-Based PFAS from Impacted Groundwater Samples from the U.S. Navy Results Underscore the Robustness of AirSCWO Technology in Eliminating PFAS and Transforming Complex Waste Streams DURHAM, N.C., March 18, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today announced the successful treatment and destruction of Light Non-Aqueous Phase Liquid (LNAPL) impacted with Per- and Polyfl...

 PRESS RELEASE

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results

Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growthClosed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in JanuaryAcquired and relaunched ultra rare disease product Galzin®Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company’s pediatric endocri...

 PRESS RELEASE

Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Suppor...

Humanetics Selects Lifecore Biomedical to Deliver CDMO Services Supporting Development of BIO 300 for the Prevention of Acute Radiation Syndrome Humanetics’ Novel Radioprotective Agent Being Developed with Funding from Department of Defense as Radiation Medical Countermeasure (MCM) Lifecore to Carry Out Tech Transfer and Analytical Method Activities, including Filling of Pilot Batch CHASKA, Minn. and MINNEAPOLIS, March 17, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: ) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), and Human...

 PRESS RELEASE

Greenwich LifeSciences Provides Update on Open Label Safety Data from ...

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update on FLAMINGO-01 open label safety data. FLAMINGO-01 Data Safety Monitoring Board (DSMB) The FLAMINGO-01 DSMB met twice in 2024, most recently in December 2024, and recommended to c...

 PRESS RELEASE

Nuvectis Pharma to Participate in the 37th Annual Roth Conference

Nuvectis Pharma to Participate in the 37th Annual Roth Conference FORT LEE, NJ, March 14, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer, will participate in a fireside chat at the 37th Annual Roth Conference taking place March 17th-19th in Dana Point, California. Event37th Annual Roth ConferenceDateMarch 17, 2025Time2:30 PM Pa...

 PRESS RELEASE

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results...

Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Company’s patented desmopressin oral solution successfully passed pivotal bioequivalence study -- Company expects to submit New Drug Application (NDA) in April 2025 - DEER PARK, Ill., March 14, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced positive results from its bioequivalence study of ET-600, a proprietary, patente...

 PRESS RELEASE

374Water Announces Appointment of Raj Melkote as Chief Technology Offi...

374Water Announces Appointment of Raj Melkote as Chief Technology Officer R&D and Engineering Executive to Drive Innovation and Growth DURHAM, N.C., March 13, 2025 (GLOBE NEWSWIRE) -- 374Water Inc. (NASDAQ: SCWO) ("374Water") (the "Company"), a global leader in waste destruction technology for the municipal, federal, and industrial markets, today announced the appointment of Raj Melkote as its new Chief Technology Officer (“CTO”). Raj Melkote brings over 30 years of experience as a Research & Development and Engineering executive with a track record of introducing and commercializing ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch